AE Wealth Management LLC Increases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Posted by Defense World Staff on Apr 16th, 2023

AE Wealth Management LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV – Get Rating) by 156.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 42,074 shares of the medical research company’s stock after purchasing an additional 25,693 shares during the quarter. AE Wealth Management LLC’s holdings in IQVIA were worth $8,620,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of IQV. Flputnam Investment Management Co. boosted its stake in shares of IQVIA by 2.8% in the fourth quarter. Flputnam Investment Management Co. now owns 1,859 shares of the medical research company’s stock valued at $381,000 after buying an additional 51 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its stake in shares of IQVIA by 59.0% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 163,220 shares of the medical research company’s stock valued at $33,441,000 after buying an additional 60,578 shares in the last quarter. Threadgill Financial LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at approximately $436,000. New York State Common Retirement Fund boosted its stake in shares of IQVIA by 6.6% in the fourth quarter. New York State Common Retirement Fund now owns 211,910 shares of the medical research company’s stock valued at $43,418,000 after buying an additional 13,056 shares in the last quarter. Finally, Sustainable Growth Advisers LP boosted its stake in shares of IQVIA by 8.0% in the fourth quarter. Sustainable Growth Advisers LP now owns 1,516,938 shares of the medical research company’s stock valued at $310,805,000 after buying an additional 112,923 shares in the last quarter. 86.20% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on IQV shares. StockNews.com started coverage on IQVIA in a research note on Thursday, March 16th. They issued a “hold” rating on the stock. Credit Suisse Group reiterated an “outperform” rating and set a $265.00 target price on shares of IQVIA in a research report on Monday, February 13th. Morgan Stanley boosted their target price on IQVIA from $240.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, February 13th. Robert W. Baird decreased their target price on IQVIA from $266.00 to $260.00 and set an “outperform” rating on the stock in a research report on Friday, January 13th. Finally, Barclays decreased their target price on IQVIA from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 4th. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Stock Performance

NYSE IQV opened at $200.35 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $165.75 and a fifty-two week high of $249.11. The stock has a market cap of $37.29 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 2.00 and a beta of 1.40. The business has a fifty day moving average of $206.98 and a 200-day moving average of $207.19. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV – Get Rating) last released its quarterly earnings results on Friday, February 10th. The medical research company reported $2.78 earnings per share for the quarter, topping analysts’ consensus estimates of $2.76 by $0.02. The company had revenue of $3.74 billion during the quarter, compared to analysts’ expectations of $3.71 billion. IQVIA had a return on equity of 31.88% and a net margin of 7.57%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.42 earnings per share. As a group, analysts predict that IQVIA Holdings Inc. will post 9.46 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the insider now directly owns 17,053 shares in the company, valued at $3,922,190. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Eric Sherbet sold 1,000 shares of the company’s stock in a transaction on Tuesday, February 14th. The stock was sold at an average price of $230.00, for a total value of $230,000.00. Following the completion of the transaction, the insider now directly owns 17,053 shares in the company, valued at $3,922,190. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 4,446 shares of the company’s stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $225.61, for a total value of $1,003,062.06. Following the sale, the insider now owns 1,973 shares of the company’s stock, valued at $445,128.53. The disclosure for this sale can be found here. Insiders own 1.50% of the company’s stock.

IQVIA Company Profile

(Get Rating)

IQVIA Holdings, Inc engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm’s life science clients.

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.